Number of patients | Number of cycles planned | Number of cycles completed | Number of GFR evaluations | Decrement in GFR | Dose modification of carboplatin | Nephrotoxicity | Dialysis | Transplant-related mortality |
---|---|---|---|---|---|---|---|---|
15 | 21 | 21 | 54 | No | No | Not more than grade 1 | No | No |
1 (A) | Single - 1 | 1 | Baseline 24hrCrCl, then 2 GFR | No | No | Grade 5 | Yes | Yes |
1 (B) | Tandem - 3 | 2 | 4 | No | No | Grade 5 | Yes | Yes |
1 (C) | Single – 1 | 1 | 3 | Yes | Dose 3 omitted | Grade 1 | No | No |
1 (D) | Single – 1 | 1 | 3 | Yes | Dose 3 omitted | Grade 2 | No | No |
1 (E) | Tandem - 3 | 2 | 4 | Yes | Cycle 2, dose 2 decreased 50%; Cycle 3 omitted | Grade 4 | Yes | No |